# Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

> **NCT01485874** · PHASE1 · TERMINATED · sponsor: **Hoosier Cancer Research Network** · enrollment: 11 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Doxil (Pegylated Liposomal Doxorubicin)
- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01485874
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-11
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Funding withdrawn due to drug unavailability
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485874, "Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01485874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*